Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast

Cancer Research

Volumn 62, Issue 1, 2002, Pages 122-128

  Chan, Kai C ^a   Bundred, Nigel J ^a   Knox, W Fiona ^a   Morris, Julie ^a   Potten, Christopher S ^b   Gee, Julia M ^c   Nicholson, Robert I ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Tenovus Cancer Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ESTROGEN RECEPTOR; GEFITINIB; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PRECANCEROUS CONDITIONS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036143027     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators
3. Incidence of and treatment for ductal carcinoma in situ of the breast
4. Duct carcinoma in situ: Predictors of local recurrence and progression in patients treated by surgery alone
5. Ductal carcinoma in situ of the breast
6. Ductal carcinoma in situ of the breast: Histologic categorisation and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein
7. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast
8. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ
9. The clinical significance of the epidermal growth factor (EGF-R) in human breast cancer: A review of 5232 patients
10. Epidermal growth factor receptor and c-erbB2 expression in normal breast tissue during the menstrual cycle
11. EGF receptor
12. Signal transduction by receptors with tyrosine kinase activity
13. Epidermal growth factor-related peptides and their receptors in human malignancies
14. Mammary tumours expressing the neu protooncogene possess elevated c-src tyrosine kinase activity
15. Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy
16. Transgenic models of breast cancer
17. Type I receptor tyrosine kinases as targets for therapy in breast cancer
18. EGF receptor tyrosine kinase inhibitors as anti-cancer agents - Preclinical and early clinical profile of ZD1839
19. Loss of heterozygosity in ductal carcinoma in situ of the breast
20. Phosphorylation of ErkI/2 mitogen activated protein kinase is associated with poor response to antihormonal therapy and decreased patient survival in clinical breast cancer
21. The relationship between ionizing radiation-induced apoptosis and stem cells in the small and large intestine
22. Transforming growth factor-B3 protects murine small intestinal crypt stem cell and animal survival after irradiation, possibly by reducing stem-cell cycling
23. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer
24. Transactivation of the EGFR receptor mediates IGF-1 stimulated Shc phosphorylation and erkI/2 activation in Cos-7 cells
25. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): Correlation with grade of associated breast invasive carcinoma
26. Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis
27. Effects of estrogen, epidermal growth factor, and transforming growth factor-α on the growth of human breast epithelial cells in primary culture
28. The pathology of ductal carcinoma in situ of the breast
29. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma
30. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases
31. Signal transduction through MAP kinase cascades
32. A pharmacokinetic/pharmacodynamic trial of ZD 1839 (IRESSA), a novel oral epidermal growth factor receptor tyrosinase kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a Phase I/II trial of continuous once-daily treatment)
33. Phase 1 study of oral ZD1839 (iressa), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
34. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage 11 breast cancer
35. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
36. Molecular characterization of intraductal breast carcinomas
37. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised Phase III trial 10853
38. Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression
39. Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers
40. Estrogen receptor positive proliferating cells in the normal and precancerous breast
41. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer